Investors Pump $257M Into Thrive’s Liquid Biopsy Test
Executive Summary
Thrive is developing CancerSEEK, a liquid biopsy test designed to detect cancers at earlier stages of disease.
You may also be interested in...
AACR 2020: Liquid Biopsy Company Guardant Health Presents Colorectal Cancer Data, Outlines Plans For Regulatory Approval
Guardant Health presented new clinical data at this week’s American Association for Cancer Research conference and outlined its growth plans as cancer testing volumes recover after the pandemic.
Breakthrough Status, Big Investments For Liquid Biopsies
The growth potential of liquid biopsy diagnostics is drawing increasing attention, with several recent breakthrough device designations from the US FDA, big funding rounds, and major acquisitions all in play.
Qiagen’s Ambitions: Standing Alone And Strengthening Infectious Disease Portfolio
Qiagen official Antoine Marchal outlines how NeuModx will strengthen its position in the infectious disease space.